Machida S, Fujiwara H and Takei Y. Informed consent for end-of-life chemotherapy in cancer patients: To what extent should we inform patients of our personal opinion? J Oncol Pharm Pract. [in press] 2018. Epub ahead of print August 2018.
2.
Gilbar PJ, McPherson I, Aisthorpe S, et al. Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian Regional Cancer Centre. J Oncol Pharm Pract. Epub ahead of print 3 January 2018. DOI: 10.1177/1078155217752077.
3.
TarimanJDBerryDLCochraneBet al.Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann Oncol2010; 21: 1145–1151.
4.
HerrimanAHallASanson-FisherRet al.Not asking patients about their preferences does make a difference. A cross-sectional study examining cancer patients preferred and perceived role in decision-making regarding their last important cancer treatment. Eur J Cancer Care2018, pp. e12871–e12871. Epub ahead of print 14 June 2018.
5.
ObeidatRFHomishGGLallyRM. Shared decision making among individuals with cancer in non-Western cultures: a literature review. Oncol Nurs Forum2013; 40: 454–463.
6.
UmezawaSFujimoriMMatsushimaEet al.Preferences of advanced cancer patients for communication on anticancer treatment cessation and the transition to palliative care. Cancer2015; 121: 4240–4249.
7.
EnzingerACWindJKFrankEet al.A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. Patient Educ Couns2017; 100: 1527–1536.
